Cargando…

Self-reported symptoms among participants in a population-based screening program

BACKGROUND: A limited number of studies have explored the association between self-reported symptoms and the risk of breast cancer among participants of population based screening programs. METHODS: We performed descriptive statistics on recall, screen-detected and interval cancer, positive predicti...

Descripción completa

Detalles Bibliográficos
Autores principales: Larsen, Marthe, Lilleborge, Marie, Vigeland, Einar, Hofvind, Solveig
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7495098/
https://www.ncbi.nlm.nih.gov/pubmed/32927237
http://dx.doi.org/10.1016/j.breast.2020.08.015
_version_ 1783582866753454080
author Larsen, Marthe
Lilleborge, Marie
Vigeland, Einar
Hofvind, Solveig
author_facet Larsen, Marthe
Lilleborge, Marie
Vigeland, Einar
Hofvind, Solveig
author_sort Larsen, Marthe
collection PubMed
description BACKGROUND: A limited number of studies have explored the association between self-reported symptoms and the risk of breast cancer among participants of population based screening programs. METHODS: We performed descriptive statistics on recall, screen-detected and interval cancer, positive predictive value and histopathological tumour characteristics by symptom group (asymptomatic, lump, and skin or nipple changes) as reported from 785,642 women aged 50–69 when they attended BreastScreen Norway 1996–2016. Uni- and multivariable mixed effects logistic regression models were used to analyze the association between symptom group and screen-detected or interval cancer. Results were presented as odds ratios and 95% confidence intervals (CI). RESULTS: A lump or skin/nipple change was reported in 6.2% of the 3,307,697 examinations. The rate of screen-detected cancers per 1000 examinations was 45.2 among women with a self-reported lump and 5.1 among asymptomatic women. Adjusted odds ratio of screen-detected cancer was 10.1 (95% CI: 9.3–11.1) and 2.0 (95% CI: 1.6–2.5) for interval cancer among women with a self-reported lump versus asymptomatic women. Tumour diameter, histologic grade and lymph node involvement of screen-detected and interval cancer were less prognostically favourable for women with a self-reported lump versus asymptomatic women. CONCLUSION: Despite targeting asymptomatic women, 6.2% of the screening examinations in BreastScreen Norway was performed among women who reported a lump or skin/nipple change when they attended screening. The odds ratio of screen-detected cancer was higher for women with versus without symptoms. Standardized follow-up guidelines might be beneficial for screening programs in order to take care of women reporting signs or symptoms of breast cancer when they attend screening.
format Online
Article
Text
id pubmed-7495098
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-74950982020-09-25 Self-reported symptoms among participants in a population-based screening program Larsen, Marthe Lilleborge, Marie Vigeland, Einar Hofvind, Solveig Breast Original Article BACKGROUND: A limited number of studies have explored the association between self-reported symptoms and the risk of breast cancer among participants of population based screening programs. METHODS: We performed descriptive statistics on recall, screen-detected and interval cancer, positive predictive value and histopathological tumour characteristics by symptom group (asymptomatic, lump, and skin or nipple changes) as reported from 785,642 women aged 50–69 when they attended BreastScreen Norway 1996–2016. Uni- and multivariable mixed effects logistic regression models were used to analyze the association between symptom group and screen-detected or interval cancer. Results were presented as odds ratios and 95% confidence intervals (CI). RESULTS: A lump or skin/nipple change was reported in 6.2% of the 3,307,697 examinations. The rate of screen-detected cancers per 1000 examinations was 45.2 among women with a self-reported lump and 5.1 among asymptomatic women. Adjusted odds ratio of screen-detected cancer was 10.1 (95% CI: 9.3–11.1) and 2.0 (95% CI: 1.6–2.5) for interval cancer among women with a self-reported lump versus asymptomatic women. Tumour diameter, histologic grade and lymph node involvement of screen-detected and interval cancer were less prognostically favourable for women with a self-reported lump versus asymptomatic women. CONCLUSION: Despite targeting asymptomatic women, 6.2% of the screening examinations in BreastScreen Norway was performed among women who reported a lump or skin/nipple change when they attended screening. The odds ratio of screen-detected cancer was higher for women with versus without symptoms. Standardized follow-up guidelines might be beneficial for screening programs in order to take care of women reporting signs or symptoms of breast cancer when they attend screening. Elsevier 2020-08-31 /pmc/articles/PMC7495098/ /pubmed/32927237 http://dx.doi.org/10.1016/j.breast.2020.08.015 Text en © 2020 The Author(s) http://creativecommons.org/licenses/by/4.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Original Article
Larsen, Marthe
Lilleborge, Marie
Vigeland, Einar
Hofvind, Solveig
Self-reported symptoms among participants in a population-based screening program
title Self-reported symptoms among participants in a population-based screening program
title_full Self-reported symptoms among participants in a population-based screening program
title_fullStr Self-reported symptoms among participants in a population-based screening program
title_full_unstemmed Self-reported symptoms among participants in a population-based screening program
title_short Self-reported symptoms among participants in a population-based screening program
title_sort self-reported symptoms among participants in a population-based screening program
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7495098/
https://www.ncbi.nlm.nih.gov/pubmed/32927237
http://dx.doi.org/10.1016/j.breast.2020.08.015
work_keys_str_mv AT larsenmarthe selfreportedsymptomsamongparticipantsinapopulationbasedscreeningprogram
AT lilleborgemarie selfreportedsymptomsamongparticipantsinapopulationbasedscreeningprogram
AT vigelandeinar selfreportedsymptomsamongparticipantsinapopulationbasedscreeningprogram
AT hofvindsolveig selfreportedsymptomsamongparticipantsinapopulationbasedscreeningprogram